GV is in line for an exit as the cancer therapy developer set terms for an offering that will raise more than $185m if it floats at the top of its range.

University of Florida's $1m seed fund backed four university spinouts in its inaugural year in sectors including industrial and healthcare.

Eli Lilly will exit the genetic sequencing system provider in a cash-and-share acquisition by 10x Genomics that followed $50m in funding.

University endowments have backed a dollar-denominated venture capital fund from M31 Capital, whose earlier investments include Grail.

Tigermed and Sinopharm-CICC contributed to a round that will support clinical testing for Hinova's pipeline of cancer and metabolic disease candidates.

Fresenius Medical Care and company founder Avera Health both took part in a round that will fund clinical trials of Alucent's vascular disease treatment.

The health management app developer has completed a series A round led by Reckitt Benckiser, which had previously invested last year.

CU Boulder's heart disease drug developer MyoKardia has been picked up by BMS after finishing clinical trials on its lead asset.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Dana-Farber Cancer Institute's cancer therapy developer raised $182m in an upsized IPO where it floated above its range.